COMMUNIQUÉS West-GlobeNewswire

Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates
28/02/2018
Galafold Expansion Continues with 360+ Fabry Patients Treated Today - on Track to Achieve FY18 Revenue Guidance of $75M-$85M Significant Progress Across Pompe Clinical, Regulatory and Manufacturing Activities - [...]
Cesca Therapeutics Inc. to Present at the 8th Spring Meeting of the International Society for BioProcess Technology (ISBiotech)
28/02/2018
RANCHO CORDOVA, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ: KOOL ) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today [...]
VitalHub Subsidiary HInext Adds 16 New Customers in New York State
28/02/2018
TORONTO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX-V: VHI ) is pleased to announce that its subsidiary HInext Inc. (“HInext”) has obtained 16 new customers in New York State, [...]
Axsome Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018
28/02/2018
NEW YORK, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM ), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, [...]
Evogene Reports Fourth Quarter and Full Year 2017 Financial Results
28/02/2018
REHOVOT, Israel, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ: EVGN ) (TASE: EVGN ), a leading biotechnology company developing novel products for life science markets through the use of a unique Computational [...]
Novelion Therapeutics Observes Rare Disease Day
28/02/2018
VANCOUVER, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN ), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare [...]
Cara Therapeutics Doses First Patient in Phase 1 Trial of Oral KORSUVA™ (CR845/difelikefalin) in Chronic Liver Disease (CLD) Patients
28/02/2018
STAMFORD, Conn., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA ), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and [...]
ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update
28/02/2018
Key updates Runway into the second half of 2019: cash of €48.0 million at year-end expected to fund operations through anticipated clinical data readouts in three different programs. First patient dosed in the Phase 1/2 [...]
Akcea Therapeutics Recognizes Rare Disease Day by Spotlighting Several Historic “Firsts” for People Living with Familial Chylomicronemia Syndrome
28/02/2018
CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA ), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious [...]
Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program
28/02/2018
GAITHERSBURG, Md., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) today announced a contract award by the Centers for Disease Control and Prevention (CDC) valued at $26 million over 12 months [...]
Syneos Health Reports Fourth Quarter and Full Year 2017 Results
28/02/2018
Highlights Combined Company net new business awards of $622.9 million for the fourth quarter and $2.55 billion for the full year 2017 representing growth of 16.5% for the full year 2017. Combined Company book-to-bill [...]
Achillion Raises Awareness for C3 Glomerulopathy With Launch of WeC3G™ Initiative as Part of Rare Disease Day 2018
28/02/2018
February 28, 2018 is the 11 th Annual Rare Disease Day Achillion sponsors initiative to help shine the light on C3G to raise awareness and understanding of this rare, chronic disease affecting the kidneys NEW HAVEN, [...]
BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema
28/02/2018
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) announced today the dosing of the first patient in APeX-S, a long-term safety trial evaluating two dosage [...]
RadNet, Inc. Announces Date of its Fourth Quarter 2017 Financial Results Conference Call
28/02/2018
LOS ANGELES, Feb. 28, 2018 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT ), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Amarin Sponsors Multiple Scientific Presentations Scheduled for 2018 American College of Cardiology Annual Scientific Session & Expo
28/02/2018
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
Solon Eiendom ASA : Key information relating to the cash dividend proposed
28/02/2018
Oslo, 28 February 2018: Solon Eiendom ASA (OSE: SOLON) Dividend amount: NOK 1.15 per share Declared currency: NOK Last day including right: 23 May 2018 Ex-date: 24 May 2018 Record date: 25 May 2018 Payment date: 4 June [...]
Orion's statutory co-operation negotiations completed
28/02/2018
ORION CORPORATION PRESS RELEASE 28 FEBRUARY 2018 at 10.45 Orion's statutory co-operation negotiations completed Orion's co-operation negotiations regarding the laboratory operations of pharmaceutical production, quality [...]
Orphazyme recognizes Rare Disease Day 2018
28/02/2018
Orphazyme A/S Investor news No. 03/2018 Copenhagen, February 28, 2018 – Orphazyme A/S , a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases today announced its support [...]
Veritas Pharma Signs Memorandum of Understanding with BioCan Technologies
28/02/2018
VANCOUVER, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ) (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of [...]

Pages